LncRNAs in CONDBITs perspectives, from genetics towards theranostics

• Main Authors: Anurogo, Dito, Parikesit, Arli Aditya, Ikrar, Taruna
• Format: Article
• Language: English
• Published: Penerbit Universiti Kebangsaan Malaysia 2019
• Online Access: http://journalarticle.ukm.my/13442/1/16808-104266-1-PB.pdf; http://journalarticle.ukm.my/13442/; http://ejournal.ukm.my/jskm/issue/view/687

LncRNAs (Long noncoding RNAs) are novel group of ncRNAs and has been discovered to be pervasively transcripted in the genome, characterized as endogenous cellular RNAs consist of more than 200 nucleotides. They are ordered in view of function, transcript length, relation with protein-coding genes and other functional DNA elements, and subcellular localization. Theranostics is a novel study in medicine that combines specific targeted biomolecules based upon molecular-based test. As novel finding in the field of molecular medicine, lncRNA is indispensable tools in theranostics based medicine that allows specific targeting of molecular pathway for diagnostics and therapeutics. LncRNAs may execute as signals, decoys, guides, and scaffolds in their natural capacities. LncRNA expression is controlled by transcriptional and epigenetic factors and processes. LncRNAs also relate detracting biological programs. Here we reviewed lncRNAs in disorders/diseasest horoughly based on CONDBITs perspectives, i.e.: cardiology, oncology, neurology and neuroscience, dermatology, the biology of molecular and bioinformatics, immunology, and technologies (related with “-omics”; transcriptomics and “nano”; nanotechnology). It was narrated the lncRNA biomarkers that abundant in cardiovascular, neurodegenerative, dermatology, and immunology perspective. However, as cancer is the most widely studied disease, more biomarkers are available for this particular case. There are abundant cancer-associated lncRNAs. The most frequent learned lncRNA molecules in cancer are HOTAIR, MALAT1, LincRNA-p21, H19, GAS5, ANRIL, MEG3, XIST, HULC. LncRNAs in cancer diagnosis and monitoring, e.g.: H19 and AA174084 (gastric), HULC (hepatocellular), PCA3 (prostate). Prognostic lncRNAs, e.g.: HOTAIR and NKILA (breast), MEG3 (meningioma), NBAT-1 (neuroblastoma), SCHLAP1 (prostate). LncRNAs predicting therapeutic responsiveness, e.g.: CCAT1 (colorectal), HOTAIR (ovarian). Thus, it is concluded that the CONDBIT perspective is useful to describe the encouraging outlook of this transcriptomics-based medicinal approach.